Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie (prior sponsor, Abbott)
• Collaborator: Paragon Biomedical
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Diagnosis of Psoriasis for 6 mo.

• BSA 10%, PASI 12 or above, PGA 3 or above

Exclusion Criteria:

• Previous exposure to either etanercept or ABT-874